Daily Sepsis Research Analysis
Analyzed 26 papers and selected 3 impactful papers.
Summary
A standardized, cell-based neutrophil assay (cellular response capacity, CRC) outperformed conventional humoral biomarkers for earlier and more precise sepsis detection and monitoring. A PRISMA-compliant meta-analysis found that restrictive initial fluid resuscitation in sepsis does not reduce mortality but lowers risks of acute kidney injury and acute respiratory distress syndrome and decreases ventilator dependence. A large prospective cohort showed that ESBL production in E. coli bacteremia is not independently associated with higher 30-day mortality after adjustment, underscoring the importance of timely appropriate empiric therapy.
Research Themes
- Cell-based immunomonitoring for early sepsis diagnosis
- Fluid resuscitation strategies and organ protection in sepsis
- Antimicrobial resistance, empiric therapy, and sepsis outcomes
Selected Articles
1. Restrictive Versus Liberal Fluid Strategy for Initial Resuscitation in Sepsis and Septic Shock: A Systematic Review and Meta Analysis.
Across nine randomized trials and additional cohort data (n=5,013), restrictive initial fluid resuscitation did not change all-cause mortality versus liberal/standard strategies but was associated with lower risks of AKI and ARDS and reduced dependence on mechanical ventilation. Trial sequential analysis suggested mortality evidence remains inconclusive.
Impact: Fluid resuscitation is foundational in sepsis; this synthesis clarifies that restrictive strategies may protect organs without affecting mortality, guiding protocol development and future trials.
Clinical Implications: Adopt individualized, restrictive fluid strategies with dynamic perfusion assessment to reduce kidney and lung complications, while recognizing no proven mortality benefit; integrate early vasopressors and avoid fluid overload.
Key Findings
- Restrictive fluid resuscitation showed no significant difference in all-cause mortality versus liberal/standard care in RCTs (RR≈0.99).
- Restrictive strategies were associated with lower incidence of AKI and ARDS.
- Dependence on mechanical ventilation decreased under restrictive fluid protocols.
- Trial sequential analysis indicated mortality evidence remains inconclusive, warranting larger trials.
Methodological Strengths
- PRISMA/MOOSE adherence with comprehensive multi-database search through November 2025.
- Inclusion of nine RCTs, random-effects modeling, and trial sequential analysis to assess conclusiveness.
Limitations
- Heterogeneity in fluid protocols, timing, and co-interventions across studies.
- Mixing RCTs with observational cohorts and incomplete reporting for some outcomes limit certainty of estimates.
Future Directions: Large pragmatic RCTs stratified by sepsis phenotypes and resuscitation phase, integrating early vasopressors and dynamic targets (e.g., capillary refill) to define optimal fluid volumes.
BACKGROUND: Intravenous fluid resuscitation is essential in early management of sepsis, but the optimal volume and resuscitation strategy are uncertain. This systematic review and meta-analysis aimed to synthesize the evidence comparing the efficacy and safety of restrictive versus liberal fluid resuscitation strategies in adults with sepsis or septic shock. METHODS: A systematic search of PubMed, Web of Science (WoS), Scopus, and CENTRAL was conducted from inception to November 2025, following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) and Meta-analysis of Observational Studies in Epidemiology (MOOSE) guidelines. Randomized controlled trials (RCTs) and observational cohort studies comparing protocolized restrictive fluid strategies with liberal or standard care were included. Primary outcomes were all-cause mortality and acute kidney injury (AKI). Random-effects models were used to calculate pooled risk ratios (RRs) and mean differences (MDs), while trial sequential analysis (TSA) assessed the conclusiveness of evidence. RESULTS: Sixteen reports from 15 unique studies (nine RCTs and six observational studies) involving 5,013 patients were included. In the analysis of RCTs, restrictive fluid therapy resulted in no significant difference in all-cause mortality (RR = 0.99; 95% CI, 0.90-1.08; I CONCLUSIONS: Restrictive fluid resuscitation does not reduce overall mortality in adults with sepsis or septic shock, but it is associated with lower AKI and ARDS risk and decreased dependence on mechanical ventilation. Evidence regarding mortality is inconclusive, highlighting the need for large-scale trials to validate this finding.
2. The cellular response capacity (CRC) as a novel immunomonitoring approach in sepsis.
A standardized neutrophil CRC assay captured systemic inflammation earlier than IL-6 and other humoral markers, with superior ROC performance in an experimental bacteremia model. In clinical cohorts, CRC (especially CD11b) discriminated sepsis from healthy controls and tracked immunologic recovery, with a stable maximal stimulation reference enabling cross-instrument comparability.
Impact: Introduces a robust, standardized cell-based diagnostic that may enable earlier sepsis recognition and real-time monitoring beyond the kinetics of conventional biomarkers.
Clinical Implications: CRC could complement CRP/PCT by offering faster detection of systemic inflammation and trajectory monitoring, potentially improving triage and timing of antimicrobials; implementation will require multicenter validation and streamlined flow cytometry workflows.
Key Findings
- CRC of neutrophil markers (CD10, CD11b, CD66b) increased dose-dependently with bacterial burden and outperformed IL-6 at low pathogen loads.
- In clinical sepsis, CRC—especially CD11b—discriminated patients from matched healthy controls and increased over time with immunologic recovery.
- A stable maximal stimulation reference point enabled cross-cohort and cross-instrument standardization; CRC tracked surgery-induced inflammation more precisely than conventional biomarkers.
Methodological Strengths
- Standardized flow cytometry framework with a stable maximal stimulation reference enabling reproducibility across instruments.
- Translational evaluation spanning an experimental bacteremia model (dose-response) and clinical sepsis cohorts with serial measurements.
Limitations
- Exact sample sizes and settings are not specified in the abstract, limiting appraisal of precision.
- Diagnostic and prognostic utility for clinical outcomes (e.g., mortality) and impact on decision-making were not tested.
- Requires specialized flow cytometry infrastructure and standard operating procedures.
Future Directions: Prospective multicenter diagnostic accuracy and impact studies comparing CRC to PCT/presepsin and integrating CRC into ED/ICU clinical pathways with outcome endpoints.
BACKGROUND: Early recognition of sepsis remains difficult in clinical practice because conventional humoral biomarkers such as C-reactive protein, procalcitonin, and interleukin-6 (IL-6) exhibit unfavorable, slow-release kinetics and rise hours after the onset of infection. Flow cytometry enables upstream, cell-based immunomonitoring, but its clinical use is restricted by poor standardization of fluorescence measurements. In this study, the neutrophil cellular response capacity (CRC) was developed and evaluated as a standardized approach for rapid assessment of systemic inflammation in bacteremia and sepsis. METHODS: The CRC is based on a flow cytometry-based framework that defines a stable maximal stimulation reference point for neutrophil granulocytes. The CRC was evaluated in a human RESULTS: In the bacteremia model, the CRC of neutrophil markers CD10, CD11b, and CD66b increased in a dose-dependent manner with increasing bacterial burden and detected inflammation at lower pathogen burdens than IL-6 and other humoral mediators, with a superior area under the receiver operating characteristic curve. In clinical sepsis, the CRC discriminated patients from age- and sex-matched healthy volunteers, with the CRC of CD11b showing the highest diagnostic performance. CRC values increased over time in patients with sepsis, consistent with immunological recovery. The maximal stimulation reference point for CD11b remained stable across inflammatory states, cohorts, and instruments. In addition, the CRC more precisely captured the onset and resolution of surgery-induced inflammation than conventional biomarkers. CONCLUSIONS: The CRC provides a rapid, standardized, and robust cell-based immunomonitoring tool that outperforms traditional humoral markers in experimental bacteremia and reliably identifies sepsis in clinical cohorts, strongly supporting its use as a novel biomarker for earlier, more precise sepsis diagnosis and monitoring.
3. Mortality risk of ESBL producers in Escherichia coli bacteraemia: a comprehensive analysis using the PROBAC cohort.
In 2,394 E. coli BSI cases across 26 hospitals, ESBL producers had lower rates of appropriate empirical therapy and higher crude 30-day mortality (14.6% vs 9.6%). After propensity score adjustment including appropriateness of empirical therapy, ESBL status was not independently associated with mortality (adjusted OR 1.12; 95% CI 0.75-1.67).
Impact: Clarifies that excess mortality in ESBL E. coli bacteremia is largely explained by baseline factors and inappropriate empirical therapy, informing stewardship and empiric coverage decisions.
Clinical Implications: Risk-stratify for ESBL and ensure rapid, appropriate empiric coverage when indicated; focus on timely therapy optimization rather than assuming ESBL status alone portends higher mortality.
Key Findings
- Among 2,394 E. coli BSIs, 13.5% were ESBL-producers; appropriate empirical therapy was lower in ESBL vs non-ESBL (53.7% vs 92.0%).
- Crude 30-day mortality was higher with ESBL (14.6% vs 9.6%; crude OR 1.61).
- After propensity score adjustment including empirical therapy appropriateness, the association attenuated and was not significant (adjusted OR 1.12, 95% CI 0.75-1.67).
- Findings were consistent across multiple propensity score applications (covariate, matching, IPW, stratification).
Methodological Strengths
- Prospective, multicenter cohort across 26 hospitals with robust sample size (n=2,394).
- Comprehensive propensity score methodology including matching, IPW, and stratified analyses; adjustment for empirical therapy appropriateness.
Limitations
- Observational design limits causal inference; residual confounding possible.
- Generalizability may be constrained by the 2016–2017 Spanish setting and local antimicrobial practices.
Future Directions: Prospective studies integrating rapid molecular resistance diagnostics with decision support to optimize empiric therapy and randomized trials comparing empiric regimens for high ESBL-risk patients.
OBJECTIVE: The incidence of bloodstream infection (BSIs) due to extended-spectrum β-lactamase (ESBL) producing Escherichia coli is increasing worldwide. There is controversy as to whether ESBL production in itself is associated with higher mortality. The aim of this study is to evaluate the impact of ESBL production on mortality in BSIs due to E. coli considering the effect of confounders. METHODS: PROBAC study is a prospective, multicentre, cohort study performed in 26 Spanish hospitals (October 2016-March 2017). All patients with E. coli BSIs were included. The outcome variable was all-cause 30-day mortality. Confounding was controlled by calculating a propensity score (PS) for ESBL production using baseline variables. PS were used as covariable, for matching, for inverse probability of treatment weight analysis and for stratified analysis within the PS quartiles. RESULTS: A total of 2394 cases were included, of which 322 (13.5%) were ESBL-producing isolates. The frequency of appropriate empirical treatment, in ESBL-producing and non-ESBL-producing isolates, was 53.7% and 92.0%, respectively. Thirty-day mortality was 14.6% in ESBL-producing isolates versus 9.6% in non-ESBL-producing isolates (P = 0.006), for a crude OR of 1.61 (95% CI: 1.14-2.27; P = 0.006). When we adjusted by PS and appropriate empirical treatment, the OR changed to 1.12 (95% CI: 0.75-1.67; P = 0.584). Other PS applications provided similar results. CONCLUSION: BSIs due to ESBL-producing E. coli were associated with higher mortality in the crude analyses; however, the estimate of the association is reduced after adjustment for baseline variables and empirical therapy, and is not significant in matched analysis.